Politics and science shouldn’t be mixed, understand the impact of this on the commercial development of pluripotent stem cells

The Scientist recently reported that the legality of federally funding human embryonic stem cell (hESC) research is being questioned in court again, and the decision may rest on a technicality. National Institutes of Health guidelines released in 2009 lifted the Bush-era restrictions on hESC research, but were met with a lawsuit by adult stem cell researchers that August. A preliminary …

The move from big pharma to stem cells is underway as Shire makes a $200M deal to purchase Pervasis

FierceBiotech recently reported that Shire is buying the biotech Pervasis Therapeutics with an eye toward boosting its regenerative medicine unit, adding the small company’s cellular therapy in mid-stage development for vascular repair in patients on hemodialysis. The buyout follows Shire’s purchase of Advanced BioHealing last year in a deal that created the business that specializes in cell-based therapies. Ireland-based Shire …